Spleen-Restricted Posttransplant Lymphoproliferative Disorder in the First Year After Kidney Transplant - A Case Report

Transplant Proc. 2022 Jul-Aug;54(6):1624-1626. doi: 10.1016/j.transproceed.2022.03.005. Epub 2022 Apr 26.

Abstract

Posttransplant lymphoproliferative disorders (PTLDs) are a feared complication after transplant. They are mostly of B cell origin and are frequently Epstein-Barr virus (EBV)-positive, particularly in early onset PTLD. Later on, non-B and EBV-negative PTLD are increasingly reported. EBV seronegative receptors (particularly when paired with an EBV seropositive donor) together with the net degree of immunosuppression-a concept often difficult to quantify-are the most consistently described risk factors for the development of PTLD. Conversely, its association with a particular immunosuppressive agent or other virus, namely cytomegalovirus (CMV) infection or disease, has been inconsistently reported. We present a challenging case where an EBV negative monomorphic peripheric T-cell lymphoma was diagnosed in the first year after kidney transplant in a patient with a recent history of CMV disease from a resistant strain.

Publication types

  • Case Reports

MeSH terms

  • Cytomegalovirus Infections* / chemically induced
  • Cytomegalovirus Infections* / complications
  • Cytomegalovirus Infections* / diagnosis
  • Epstein-Barr Virus Infections* / complications
  • Epstein-Barr Virus Infections* / diagnosis
  • Herpesvirus 4, Human
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Kidney Transplantation* / adverse effects
  • Lymphoproliferative Disorders* / diagnosis
  • Lymphoproliferative Disorders* / etiology
  • Spleen

Substances

  • Immunosuppressive Agents